Virology markers after participation EYP001-103 study part B

Virology markers after participation EYP001-103 study part B - EYP001-103 ancillary study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48213

Enrollment

Registered

2019-06-17

Start date

2019-06-21

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CHB Chronic hepatitis B infection hepatitis B

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All patients have: Participated in the EYP001-103 study part B Have given voluntary written informed consent

Exclusion criteria

Exclusion criteria: Patients are excluded if: They are unable to come to the AMC for the study visit

Design outcomes

Primary

Measure	Time frame
Serum/plasma quantitative: HBV DNA, HBsAg, HBcrAg and HBV RNA.	—

Secondary

Measure	Time frame
The current use of antiviral medication.	—

Countries

Netherlands

Outcome results